Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by Wall Street Zen

Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued on Saturday.

KPTI has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (down from $15.00) on shares of Karyopharm Therapeutics in a research report on Thursday, October 9th. HC Wainwright raised Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Monday, October 13th. Royal Bank Of Canada decreased their price target on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Finally, Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Karyopharm Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI opened at $5.16 on Friday. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $14.24. The firm’s 50-day simple moving average is $6.18 and its 200 day simple moving average is $5.39. The firm has a market cap of $87.98 million, a price-to-earnings ratio of -0.36 and a beta of 0.35.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The business had revenue of $44.04 million for the quarter, compared to analysts’ expectations of $39.56 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several large investors have recently bought and sold shares of KPTI. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics during the second quarter worth approximately $45,000. XTX Topco Ltd bought a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. Silverback Asset Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 40.0% during the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after buying an additional 20,000 shares in the last quarter. Bank of America Corp DE grew its position in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $163,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).